<?xml version='1.0' encoding='utf-8'?>
<document id="24982385"><sentence text="Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab."><entity charOffset="29-41" id="DDI-PubMed.24982385.s1.e0" text="capecitabine" /></sentence><sentence text="Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer"><entity charOffset="0-12" id="DDI-PubMed.24982385.s2.e0" text="Capecitabine" /><entity charOffset="60-74" id="DDI-PubMed.24982385.s2.e1" text="5-fluorouracil" /><pair ddi="false" e1="DDI-PubMed.24982385.s2.e0" e2="DDI-PubMed.24982385.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24982385.s2.e0" e2="DDI-PubMed.24982385.s2.e1" /></sentence><sentence text=" This study was designed to investigate whether co-administration of the monoclonal antibody bevacizumab (BVZ) shows potential to modulate the plasma disposition of capecitabine (CCB) and its metabolites"><entity charOffset="165-177" id="DDI-PubMed.24982385.s3.e0" text="capecitabine" /><entity charOffset="179-182" id="DDI-PubMed.24982385.s3.e1" text="CCB" /><pair ddi="false" e1="DDI-PubMed.24982385.s3.e0" e2="DDI-PubMed.24982385.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24982385.s3.e0" e2="DDI-PubMed.24982385.s3.e1" /></sentence><sentence text="" /><sentence text="Nine patients treated with CCB and BVZ for advanced colorectal cancer entered this pharmacokinetic study"><entity charOffset="27-29" id="DDI-PubMed.24982385.s5.e0" text="CCB" /></sentence><sentence text=" In the first cycle CCB was given alone at doses of 1,250 mg/m2 bi-daily for two weeks with one week rest"><entity charOffset="20-22" id="DDI-PubMed.24982385.s6.e0" text="CCB" /></sentence><sentence text=" In the second cycle BVZ co-administration started simultaneously with oral intake of CCB by short infusion of 7"><entity charOffset="86-88" id="DDI-PubMed.24982385.s7.e0" text="CCB" /></sentence><sentence text="5 mg/kg" /><sentence text="" /><sentence text="Mean plasma concentration time curves of CCB and its metabolites were insignificantly lower in the BVZ combination regimen compared to CCB monotherapy"><entity charOffset="41-43" id="DDI-PubMed.24982385.s10.e0" text="CCB" /><entity charOffset="135-137" id="DDI-PubMed.24982385.s10.e1" text="CCB" /><pair ddi="false" e1="DDI-PubMed.24982385.s10.e0" e2="DDI-PubMed.24982385.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24982385.s10.e0" e2="DDI-PubMed.24982385.s10.e1" /></sentence><sentence text=" After repeated cycles of BVZ no significant pharmacokinetic interaction was observed" /><sentence text="" /><sentence text="From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient"><entity charOffset="121-123" id="DDI-PubMed.24982385.s13.e0" text="CCB" /></sentence><sentence text="" /></document>